EP1317275A1 - Medicament comprenant une sequence d'adn codant la proteine koc liant l'arn, une proteine koc ou une sequence d'adn du promoteur koc - Google Patents

Medicament comprenant une sequence d'adn codant la proteine koc liant l'arn, une proteine koc ou une sequence d'adn du promoteur koc

Info

Publication number
EP1317275A1
EP1317275A1 EP01957753A EP01957753A EP1317275A1 EP 1317275 A1 EP1317275 A1 EP 1317275A1 EP 01957753 A EP01957753 A EP 01957753A EP 01957753 A EP01957753 A EP 01957753A EP 1317275 A1 EP1317275 A1 EP 1317275A1
Authority
EP
European Patent Office
Prior art keywords
koc
cells
dna sequence
protein
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01957753A
Other languages
German (de)
English (en)
Inventor
Friederike MÜLLER
Thomas Gress
Guido Adler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10106829A external-priority patent/DE10106829A1/de
Application filed by Individual filed Critical Individual
Publication of EP1317275A1 publication Critical patent/EP1317275A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Definitions

  • the present invention relates to a medicament which contains an RNA-binding protein KOC or a DNA sequence coding for this protein, preferably inserted on a vector.
  • the present invention further relates to a diagnostic method with regard to malignant tumors associated with the expression of KOC and various uses of the medicament according to the invention, preferably for artificially inducing the pluripotency of body cells.
  • the present invention also relates to a DNA sequence of the KOC promoter, the KOC promoter being characterized in that it is activated only in embryonic tissues or malignant tumors, and various uses of the KOC promoter.
  • ES cells divisible, undifferentiated cells
  • ES cells can differentiate into mesenchymal cells by treatment with the "bone morphogenetic protein 4" (bmp4).
  • bmp4 bone morphogenetic protein 4
  • these cells can also be manipulated by defined culture conditions such that three-dimensional, tissue-like structures with organ-specific expression patterns be developed.
  • pluripotency of stem cells can be seen in the fact that it has been possible to implant neuronal stem cells in mice with destroyed bone marrow, which differentiate there into blood cells.
  • the invention is essentially based on the technical problem of providing means with which a differentiation of a mature cell type into an embryonic phenotype that is divisible but still has characteristics of the respective differentiated cell is made possible.
  • KOC KH domain containing protein overexpressed in cancer
  • RNA-binding proteins are highly conserved, functionally important structures of RNA-binding proteins that are responsible for direct mRNA binding. Studies have shown that RNA-binding proteins play a central role in the post-transcriptional regulation of gene expression. In this function, RNA-binding proteins are essential for the regulation of growth and development. Examples include patterning and cellular differentiation during embryonic development.
  • Two mechanisms of post-transcriptional gene regulation by proteins containing KH domains are the control of the mRNA stability and the specific subcellular localization of the mRNA. Although a number of proteins containing KH domains have already been identified, no KH protein has so far been shown to be able to reverse the phenotype of differentiated cells to a phenotype of immature, undifferentiated, divisible cells and thus to be possible therapeutic agent is suitable for the production of syngeneic stem cell populations which provide large numbers of divisible, specifically differentiable cells.
  • RNA-binding protein KOC RNA-binding protein KOC
  • a mature cell type can be dedifferentiated into an embryonic phenotype, but which still bears the characteristics of the differentiated cell, so that stem cells of any cell type can be generated in the same organism.
  • the KOC gene reverts the phenotype of differentiated cells into a phenotype of immature, undifferentiated, divisible cells.
  • the RNA-binding protein KOC is suitable as a possible therapeutic agent for the production of syngeneic stem cell populations that use large numbers of divisible, specifically differentiable cells Make available, which can then be used, for example, in the field of transplantation medicine and oncology up to the development of biologically functional replacement organs. Furthermore, the RNA-binding protein KOC can be used to influence physiological or physical aging-induced aging processes, for example human skin.
  • the pre B-cell model showed that, for example, the DNA synthesis of the KOC / p210 cells is significantly stronger compared to that of the p210 cells and that the KOC / p210 cells compared to the p210 cells have a large number of embryonic cells Up-regulate markers, or down-regulate markers that distinguish adult pre-B cells from fetal pre-B cells. Cells "re-differentiated" with the KOC gene are significantly less sensitive to cell death induced by radiation and dexamethasone than untreated cells.
  • KOC thus differs fundamentally from conventional growth factors used to date, which always only stimulate the proliferation of a differentiated cell type or transform a cell type into a malignant phenotype.
  • the properties mentioned result in numerous potential applications for KOC in transplantation medicine and cancer treatment.
  • the use of KOC is important for the development of new techniques for the restoration and regeneration of damaged organs (organ replacement), especially at the level of the generation of type-specific syngeneic stem cells and artificial tissue, such as in diseases such as Alzheimer's (neuronal stem cells), diabetes (pre- Beta cells), heart failure (precursor to cardiac muscle cells), liver (precursor to hepatocytes).
  • the use of KOC in the case of skin injuries, such as burns can in the future by inducing rapid extracorporeal multiplication of Skin cells may be important for transplant purposes.
  • results for KOC include following areas of application:
  • KOC itself or the gene encoding this protein
  • the possibility of inactivating KOC in diseases which are associated with an excessively high activity of KOC or an excessively high expression of the gene can also be therapeutically useful.
  • Such inactivation can take place at various levels, for example at the genetic level ("knock out", inhibition of translation by means of antisense RNAs, ribozymes or aptamers) or protein level (via inhibiting ligands, for example antibodies or antagonists, etc.).
  • the DNA sequence of the KOC promoter was also cloned and sequenced in the course of the investigations leading to the present invention, it being shown that this is only activated in embryonic tissue or malignant tumors.
  • the present invention thus relates to a DNA sequence of the KOC promoter which comprises the nucleic acid sequence shown in FIG. 9 or a nucleic acid sequence which deviates therefrom and whose biological function essentially corresponds to that of the KOC promoter.
  • a different nucleic acid sequence used in connection with the KOC promoter in the present invention refers to any nucleic acid sequence which differs from the nucleic acid sequence shown in FIG. 9 by the deletion, addition or substitution of bases, however the biological function of the Promotors is retained, ie to be able to control the transcription of a gene, the promoter being activated essentially only in embryonic tissue or malignant tumors.
  • the deviating nucleic acid sequences are preferably nucleic acid sequences which hybridize with the nucleic acid sequence shown in FIG. 9, reference being made to the definition below with regard to the term “hybridize”, or fragments of the nucleic acid sequence shown in FIG. 9.
  • the "different nucleic acid sequences" are 70%, more preferably 80% and most preferably 90% identical to the DNA sequence of Figure 9.
  • the present invention also relates to a medicament which contains a DNA sequence which codes for an RNA-binding protein KOC with the amino acid sequence shown in FIG. 1, or a DNA sequence which contains the nucleic acid sequence shown in FIG.
  • the DNA sequence is preferably cDNA.
  • the present invention further relates to a pharmaceutical composition containing a DNA sequence of the promoter KOC according to the invention or a DNA Se acid sequence, the binding for a protein having the biological properties of an RNA encoding the protein KOC, wherein said DNA sequence of the DNA sequence of Figure 1 in the codon sequence due to the degeneration of genetic codes, hybridizes with the above DNA sequences or is a fragment, an allelic variant or another variant of the above DNA sequences.
  • hybridized used in the present invention refers to conventional hybridization conditions, preferably to hybridization conditions in which 6xSSC, 1% SDS, IxDenhardts solution is used and the hybridization temperatures between 35 ° C. and 70 ° C., preferably be at 45 ° C.
  • washing is preferably carried out with 2xSSC, 1% SDS or with 0.2xSSC (stringent conditions) at temperatures between 40 ° C. and 75 ° C., preferably at 50 ° C. (for the definition of SSC and Denhardts solution see Sambrook et al ., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1989)).
  • Stringent hybridization conditions are particularly preferred, as described, for example, in Sambrook et al., Supra, or Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
  • variant or fragment used in the present invention encompass DNA sequences which differ from the sequences indicated in FIG. 1 by deletion (s), insertion (s), exchange (s) and / or others in the prior art Distinguish known modifications or comprise a fragment of the original nucleic acid molecule, the protein encoded by these DNA sequences still having the biological properties of the RNA-binding protein and being biologically active in mammals. This also includes allele variants.
  • Methods for generating the above changes in the DNA sequence are known to the person skilled in the art and are described in standard works in molecular biology, for example in Sambrook et al., Supra. The person skilled in the art is also able to determine whether a protein encoded by a DNA sequence modified in this way still has the biological properties of the RNA-binding protein KOC. Below are all these DNA sequences are generally referred to as "KOC DNA sequences”.
  • a further preferred embodiment of the present invention relates to antisense RNA which is characterized in that it is complementary to the above DNA sequences and can reduce or inhibit the synthesis of the protein encoded by these DNA sequences and a ribozyme which is characterized in that that it can specifically bind to and cleave part of the above DNA sequences and to the RNA transcribed from these DNA sequences, thereby reducing or inhibiting the synthesis of the protein encoded by these DNA sequences.
  • antisense RNAs and ribozymes are preferably complementary to a coding region of the mRNA.
  • the person skilled in the art is able to prepare and use suitable antisense RNAs based on the disclosed DNA sequences. Suitable procedures are described for example in EB-B1 0223399 or EP-A1 0458.
  • Ribozymes are RNA enzymes and consist of a single strand of RNA. These can intermolecularly cleave other RNAs, for example the mRNAs transcribed by the DNA sequences according to the invention.
  • these ribozymes must have two domains, (1) a catalytic domain and, (2) a domain that is complementary to the target RNA and can bind to it, which is a prerequisite for cleaving the target RNA.
  • a catalytic domain a domain that is complementary to the target RNA and can bind to it, which is a prerequisite for cleaving the target RNA.
  • the present invention thus also includes medicaments containing these vectors or expression vectors.
  • vector refers to a plasmid (pUC18, pBR322, pBlueScript, etc.), a virus or another suitable vehicle.
  • the DNA molecule according to the invention is furcally linked in the vector to regulatory elements which allow its expression in prokaryotic or eukaryotic host cells.
  • regulatory elements for example a promoter
  • such vectors typically contain an origin of replication and specific genes which allow the phenotypic selection of a transformed host cell.
  • the regulatory elements for expression in prokaryotes for example E.
  • coli include the lac, trp promoter or T7 promoter, and for expression in eukaryotes the AOX1 or GAL1 promoter in yeast and the CMV, SV40 , RSV, metallothione and polyhedrin promoter, CMV or SV40 enhancer for expression in animal cells.
  • Suitable regulatory sequences are also described in Goeddel: Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Further examples of suitable promoters are the metallothionein I and the polyhedrin promoter.
  • Suitable expression vectors for E. coli include, for example, pGEMEX, pUC derivatives, pGEX-2T, pET3b and pQE-8.
  • Vectors suitable for expression in yeast include pY100 and Ycpadl, for expression in mammalian cells pMSXND, pKCR, pEFBOS, cDM8 and pCEV4, and of pcDNAI / amp, pcDNAI / neo, pRc / CMV, pSV2gpt, pSV2neo, pSV2-dhfr Vectors derived from pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg.
  • the expression vectors according to the invention also include vectors derived from bacuiovirus for expression in insect cells, for example pAcSGHisNT-A.
  • the KOC-DNA sequences described above which may also comprise a DNA sequence of the KOC promoter, are preferably inserted into a vector suitable for gene therapy, for example under the control of a tissue-specific promoter, and introduced into the cells.
  • the vector containing the DNA sequences described above is a virus, for example an adenovirus, vaccinia virus or retrovirus. Retroviruses are particularly preferred. Examples of suitable retroviruses are MoMuLV, HaMuSV, MuMTV, RSV or GaLV. Vectors suitable for gene therapy are also disclosed in WO 93/04701, WO 92/22635, WO 92/20316, WO 92/19749 and WO 92/06180.
  • the KOC-DNA sequences described above can also be transported to the target cells in the form of colloidal dispersions. These include, for example, liposomes or lipoplexes (Mannino et al., Biotechniques 6 (1988), 682). Finally, the KOC-DNA sequences or the KOC protein can be administered locally, for example in the form of a cream, ointment, etc.
  • RNA-binding protein KOC RNA-binding protein
  • suitable control sequences include, for example, in vitro recombination techniques, synthetic methods and in vivo recombination methods, as are described, for example, in Sambrook et al., Supra.
  • the DNA sequences according to the invention can also be inserted in connection with a DNA coding for another protein or peptide, so that KOC can be expressed, for example, in the form of a fusion protein.
  • An essential goal in the diagnosis of malignant diseases is the specific and sensitive detection of early malignant changes.
  • more and more gene mutations that occur in the context of the adenoma-carcinoma sequence are used in epithelial tumors.
  • the disadvantage of these methods is that gene mutations sometimes occur in normal tissues, such as, for example, ki-ras in normal pancreatic tissues or in highly inflammatory tissues, which makes it impossible to distinguish between chronic, inflammatory or tumorous tissues, which are of great therapeutic importance .
  • the aim of the research is therefore to identify genes that are only expressed / upregulated in malignant degenerate cells and are therefore suitable for unambiguous tumor diagnosis.
  • KOC is expressed in pancreatic cancer, but not in normal pancreatic tissue or in chronic pancreatitis. This finding that KOC is only expressed in malignant tissues (organs or cells) but not in benign tissues has been confirmed in many different tissues and cancers. Please refer to Tab. 1.
  • KOC is therefore suitable for the differential diagnosis between malignancy and benignity, for example in the case of inflammation, of a tissue, preferably of the pancreas or colon.
  • KOC is particularly characterized by the fact that its expression can be detected very early in the development of cancer, long before any auto-antibodies against KOC can be formed.
  • KOC enables the differentiation of different stages of malignancy, especially in pancreatic and colon carcinoma.
  • the present invention also relates to diagnostic methods for the detection of a malignant tumor associated with the expression of KOC or its precursors, in which a sample with a probe suitable for specific hybridization with the mRNA transcribed from a KOC-DNA sequence or a primer or an antibody against the KOC protein or a fragment thereof and then directly or indirectly determines whether the concentration of KOC and / or the KOC mRNA in the sample differs from a control sample.
  • a sample with a probe suitable for specific hybridization with the mRNA transcribed from a KOC-DNA sequence or a primer or an antibody against the KOC protein or a fragment thereof then directly or indirectly determines whether the concentration of KOC and / or the KOC mRNA in the sample differs from a control sample.
  • the person skilled in the art knows methods for suitable sampling and also suitable control samples.
  • the control sample is preferably a tissue which corresponds to the same tissue as the tissue affected by the tumor, but comes from a healthy source.
  • An increased KOC expression compared to the control sample is a diagnostic sign of a tumor or a predisposition to a tumor.
  • the probes that can be used for this diagnostic method include primers based on the KOC-DNA sequences, for example for PCR, RT-PCR or aptamer diagnostics (SELEX method).
  • the probes (or primers) are oligonucleotides that comprise a nucleic acid region that hybridizes under stringent conditions with at least 10, preferably at least 15 consecutive nucleotides of the sequence of FIG. 1 or naturally occurring variants thereof.
  • the probe (or the primer) can also carry a label, for example a radioisotope, a fluorescent compound, an enzyme or an enzyme cofactor.
  • a label for example a radioisotope, a fluorescent compound, an enzyme or an enzyme cofactor.
  • the person skilled in the art is also familiar with conditions which allow that only the KOC mRNA is not amplified in the PCR etc. but not the KOC DNA or that a distinction can be made between DNA amplification products and mRNA amplification products, for example by treating the sample with DNAse or by using primers which also lead to the amplification of intron regions, so that a DNA amplificate is longer compared to the mRNA amplificate.
  • an oligo (dT) anchored primer for PCR, RT-PCR etc. can also be used.
  • the antibodies for the diagnostic method according to the invention can be monoclonal, polyclonal or synthetic antibodies or fragments thereof.
  • fragment means all parts of the monoclonal antibody (for example Fab, Fv or “single chain Fv” fragments) which have the same epitope specificity as the complete antibody. The production of such fragments is known to the person skilled in the art.
  • the antibodies according to the invention are preferably monoclonal antibodies. These antibodies can be produced according to standard procedures, the KOC protein or a (synthetic) fragment thereof preferably serving as an immunogen. Methods for obtaining monoclonal antibodies are known to the person skilled in the art.
  • a preferred embodiment of the method according to the invention relates to the differential diagnosis between chronic pancreatitis and pancreatic carcinoma.
  • the present invention relates to a diagnostic kit for performing the diagnostic method according to the invention, which contains a probe suitable for specific hybridization with a mRNA transcribed from a KOC-DNA sequence or a primer and / or an anti-KOC antibody or a fragment thereof.
  • a probe suitable for specific hybridization with a mRNA transcribed from a KOC-DNA sequence or a primer and / or an anti-KOC antibody or a fragment thereof Depending on the configuration of the diagnostic kit, the sample or the probe or the primer or the antibody or the fragment thereof can be immobilized.
  • the antibodies can also be present in the liquid phase, for example in immunoassays.
  • the antibodies can be labeled in different ways. Suitable markers and labeling methods are known in the art. Examples of immunoassays are ELISA and RIA.
  • the medicament according to the invention allows a number of (therapeutic) measures to be carried out.
  • the medicament is preferably combined with a suitable carrier.
  • suitable carriers and the formulation such medicinal products are known to the person skilled in the art.
  • Suitable carriers include, for example, phosphate-buffered saline solutions, water, emulsions, for example oil / water emulsions, wetting agents, sterile solutions, etc.
  • the medicaments can be administered orally or parenterally. Methods for parenteral administration include topical, intraarterial, intramuscular, subcutaneous, intramedullary, intrathecal, intravenous, intravenous, intraperitoneal, or intranasal administration.
  • the present invention thus relates to the use of the compounds described above (KOC-DNA sequences / KOC-protein) for artificially inducing the pluripotency of body cells. This is e.g. important for the development of replacement organs, especially for the production of artificial pancreatic, liver or nerve tissue.
  • the present invention also relates to the use of the above compounds for the production of tissues or organs via the differentiation of stem cell populations.
  • the present invention also relates to the use of the compounds described above (KOC DNA sequences / KOC protein) for improving the ex vivo expansion of hematopoietic stem cells, for example for autologous bone marrow transplants.
  • KOC DNA sequences / KOC protein for improving the ex vivo expansion of hematopoietic stem cells, for example for autologous bone marrow transplants.
  • syngeneic progenitor cells can be generated without "purging". This makes autologous transplants possible on a much larger scale than before.
  • the cells to be expanded can be clearly characterized beforehand in FACS (Fluorescence activated Cell Sorting), so that an expansion of malignant cells is excluded. Immunological problems, which often occur with allogeneic transplantation, are excluded.
  • the present invention also relates to the use of the above compounds for high dose chemotherapy.
  • KOC stem cells are less sensitive to chemotherapy or radiation therapy. That under therapy with expression of KOC, the number of re-infusions of expanding stem cells required is reduced. The subsequent shutdown of KOC can then restore the normal sensitivity of the cells to noxae / apoptotic stimuli after the completion of chemotherapy or radiation therapy.
  • the present invention thus also relates to the use of the above compounds for producing a prophylactic effect in chemotherapy or radiation therapy.
  • the present invention also relates to the use of the above compounds to produce a prophylactic effect on skin exposed to radiation.
  • the donor marrow can be transfected with KOC in an allogeneic bone marrow transplant.
  • a faster and less complicated engraftment is then to be expected after the transplant.
  • the present invention also relates to the use of the above compounds for the improvement of the engraftment in allogeneic bone marrow transplants.
  • KOC can also contribute to the slowing down or reversal of aging processes, the aging processes preferably being aging processes in the area of the vascular endothelium, neurons, keratinocytes and myocytes.
  • the present invention also relates to the use of the above compounds for slowing and / or reversing through physiological or physical pollutants induced aging processes, preferably aging processes, which are induced for example by pollutants, such as UV radiation and other environmental influences.
  • KOC gene or protein
  • a suitable carrier for example, as liposomes, lotions, plasters, plasters, bandages, injections, etc.
  • This use also includes a cosmetic application of KOC (gene or protein) on the skin to influence acid skin / wrinkles.
  • the present invention further relates to the use of the above compounds for the regeneration of skin defects or for accelerated wound healing.
  • This also includes the formation of granulation tissue, e.g. after trauma, burns or in the context of UIcera cruris of different origins.
  • the present invention thus relates to the use of the compounds described above (KOC-DNA sequences / KOC-protein) for immunizing an individual, for example an animal or a human, against malignant tumors associated with the expression of KOC and their precursors.
  • the present invention relates to a medicament suitable therefor which contains these compounds in an amount suitable for the immunization of an individual.
  • the KOC protein can be in wild-type or modified form.
  • the latter form includes changes in the amino acid sequence, such as additions, deletions, substitutions and / or inversions of one or more amino acids.
  • Fragments of the KOC proteins can also be present as such or in conjunction with carriers, the fragments having a wild-type or an altered amino acid sequence can.
  • the carriers do not act as immunogenic in the individual.
  • Such carriers can be individual's own proteins or foreign proteins or fragments thereof. Carriers such as serum albumin, fibrinogen or transferrin or a fragment thereof are preferred. It is particularly favorable if the fragments of the KOC proteins contain epitopes which are recognized by cytotoxic T cells, for example CD8 + T cells, and which can induce a cytotoxic immune response.
  • Such epitopes of the KOC proteins can be determined by methods known to the person skilled in the art, in particular by using a software of the NIH (NIH bioinform at ionse rv ice http: /bimas.dcrt.nih.gov.cgi-bin/molbio/ken_parker_comboform) become. It can also be advantageous if different of the KOC proteins or fragments thereof, to which the above statements apply accordingly, are present at the same time. For the production of the KOC proteins or their fragments, in addition to the above statements, reference is made to Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1989).
  • KOC-DNA sequence If used to immunize an individual, it must be in an expressible form, i.e. as such it can be present together with elements suitable for its expression or in connection with a vector. Reference is made to the above explanations.
  • malignant tumors and their precursors encompasses malignant tumors of any kind and origin, which are associated with the expression of KOC, and their precursors.
  • malignant tumors and their precursors can be carcinomas of epithelial origin, in particular pancreas, colon, breast, bronchial and anogenital carcinomas.
  • the term "amount suitable for immunization of an individual” includes any amount of the KOC protein to which the above statements apply, or an expressible KOC DNA sequence for which the above explanations apply accordingly, with which an individual can be immunized.
  • the amount depends on whether the KOC protein or the expressible KOC DNA sequence is used.
  • the amount also depends on whether the immunization of the individual aims more at induction of antibodies directed against the KOC protein or at stimulation of cytotoxic T cells directed against the KOC protein, eg CD8 + T cells. Both possibilities of immunization can be achieved by the present invention. Furthermore, the amount depends on whether the immunization is intended as a prophylactic or therapeutic treatment.
  • the age, gender, and weight of the individual speak a role in determining the amount. It is favorable if the individual is injected with 100 ⁇ g - 1 g of the KOC protein or 10 6 - 10 12 MOI of a recombinant virus containing an expressible KOC-DNA sequence.
  • the injection can take place intramuscularly, subcutaneously, intradermally or in any other form of application in several places of the individual.
  • the drug contains immunization adjuvants such as GM-CSF or Freund's adjuvant to immunize the individual.
  • a non-human mammal (“knock-out”) can be provided by conventional methods, the KOC gene of which is changed.
  • a method is favorable which comprises the following steps:
  • step (b) preparation of embryonic stem cells from a non-human mammal (preferably mouse); (c) transforming the embryonic stem cells from step (b) with the DNA fragment from step (a), the KOC gene in the embryonic stem cells being changed by homologous recombination with the DNA fragment from (a),
  • step (d) culturing the cells of step (c),
  • step (e) selection of the cultured cells from step (d) for the presence of the heterologous sequence, in particular the selectable marker,
  • step (f) Generating chimeric non-human mammals from the cells of step (e) by injecting these cells into mammalian blastocysts (preferably mouse blastocysts), transferring the blastocysts into pseudo-pregnant female mammals (preferably mouse) and analyzing the progeny obtained for a change in the KOC gene.
  • mammalian blastocysts preferably mouse blastocysts
  • pseudo-pregnant female mammals preferably mouse
  • step (c) the mechanism of homologous recombination (cf. R.M. Torres, R. Kühn, Laboratory Protocols for Conditional Gene Targeting, Oxford University Press, 1997) is used to transfect embryonic stem cells.
  • the homologous recombination between the DNA sequences present in a chromosome and new, added cloned DNA sequences enables the insertion of a cloned gene into the genome of a living cell instead of the original gene.
  • embryonic germ cells can be used to obtain via chimeras animals that are homozygous for the desired gene or the desired gene part or the desired mutation.
  • embryonic stem cells refers to any embryonic stem cells from a non-human mammal that are suitable for mutating the KOC gene.
  • the embryonic stem cells are preferably from the mouse, in particular the cells E14 / 1 or 129 / SV.
  • vector encompasses any vector which, by recombination with the DNA of embryonic stem cells, alters the KOC gene. made possible.
  • the vector preferably has a marker which can be used to select for existing stem cells in which the desired recombination has taken place.
  • a marker is, for example, the loxP / tk neo-cassette, which can be removed from the genome again using the Cre / loxP system.
  • the present invention provides a non-human mammal whose KOC gene is altered.
  • This change can be a function deactivation.
  • the function of the KOC protein can be examined selectively. It is also possible to find substances, drugs and therapeutic approaches that can be used to selectively influence the function.
  • the present invention therefore provides a basis for acting on a wide variety of diseases. Such diseases are e.g. induction of cancer due to errors in the control of cell proliferation.
  • the mammal with altered KOC function enables studies to be carried out as to whether weakened, if not no, tumor development is observed in these animals through the application of various cancerogens. The animal represents a new disease model for the development of new therapeutic approaches.
  • the present invention also relates to the use of the DNA sequence of the KOC promoter shown in FIG. 9 or the nucleic acid sequence which deviates therefrom, the biological function of which essentially corresponds to that of the KOC promoter for the isolation and / or enrichment and / or selective multiplication of stem cells , preferably non-human embryonic stem cells.
  • Stem cells are the primary cells from which the individual tissues of an organism develop. Because all cell types in an organism consist of just one stem cell, the zygote (fertilized egg cell), all stem cells have precursors that have different abilities (potencies) to form new tissues depending on the development stage of the individual.
  • stem cells for example embryonic stem cells from the "mixed culture”.
  • Genetic manipulation makes it possible to introduce genetic selection markers into the cells whose gene products ensure selective survival of the stem cells under certain culture conditions.
  • a gene product can cause resistance to certain antibiotics. All cells that do not express this resistance gene can be eliminated by adding the respective antibiotic in the culture medium.
  • a crucial prerequisite for a selection of stem cells is that the respective selection marker is under the control of a promoter that is activated exclusively in the stem cells. Since the KOC promoter is only activated during this time, it can be used as a control unit for the selection of stem cells.
  • infection / transfection of a vector in which a selection marker is under the control of the KOC promoter gives the stem cells a selection advantage under conditioned culture conditions (eg addition of antibiotics) compared to cells that are no longer in the embryonic state or already differentiated a selection advantage.
  • suitable vectors and suitable selection markers for example the neo-gene / G418 system, are known to the person skilled in the art; see also the above explanations regarding the description of the non-human mammal.
  • the person skilled in the art is also familiar with suitable cultivation methods and media in order to be able to cultivate stem cells, for example embryonic stem cells; see, for example, DE 196 08 813 C2, EP-B1 0 695 351.
  • the "basic medium" which contains, for example, the antibiotic in a suitable concentration for selection, can be any medium which is usually used for the cultivation of mammalian cells.
  • the cells are grown in the above medium under suitable conditions, optionally with (partial) renewal of the medium at suitable time intervals. Suitable conditions, for example with regard to suitable containers, temperature, relative atmospheric humidity, 0 2 content and C0 2 content of the gas phase, are known to the person skilled in the art.
  • the cells are cultured in the medium under the following conditions: (a) 37 ° C, (b) 100% rel. Humidity, (c) 10% 0 2 and (d) 5% C0 2 .
  • the person skilled in the art can also monitor the desired inhibition of cell differentiation on the basis of customary criteria (morphological criteria, presence or absence of specific surface proteins, etc.).
  • the present invention also relates to the use of the DNA sequence of the KOC promoter shown in FIG. 9 or the nucleic acid sequence which deviates therefrom, the biological function of which essentially corresponds to that of the KOC promoter, for determining the degree of differentiation or dedifferentiation of a cell or a tissue.
  • it is favorable to combine the D NA sequence from FIG. 9 or the nucleic acid sequence deviating therefrom with a reporter gene and to introduce the construct into the cell or the tissue and to demonstrate the expression of the reporter gene, which provides information about gives the degree of differentiation or degree of differentiation.
  • the present invention also relates to a diagnostic kit for carrying out the diagnostic method described above, which contains a probe or a primer suitable for specific hybridization with a DNA sequence of the KOC promoter.
  • the statements made above apply mutatis mutandis to the diagnostic kit relating to the KOC protein or KOC gene.
  • the inventors have characterized pairs of primers which are ideally suited for the purposes mentioned above, for example as a tumor indicator. These can be provided as part of the kit.
  • the preferred primers are:
  • primer pair combinations are very particularly preferred:
  • the conventional tumor markers used so far in the clinic are usually acute phase proteins, which increase in their measurable value in the course of a tumor disease, but also in numerous pathophysiological conditions, e.g. renal insufficiency, inflammation, etc., above the normal value in serum are to be found elevated.
  • These tumor markers only have their clinical significance if, firstly, they are significantly increased and secondly, their value changes in the course of a disease or therapy. This means that most of the common tumor markers are only suitable for course assessment or therapy evaluation. However, they are primarily of no diagnostic value.
  • KOC as a tumor indicator makes it possible for the first time to predict with accidental findings, e.g. in imaging procedures, with excellent specificity and sensitivity whether a lesion is a malignant or benign mass.
  • KOC provides this information with regard to any tissue and is therefore a universally applicable tumor indicator for confirming the diagnosis of Is mass. It is also noteworthy that KOC is not affected in its expression behavior by other pathophysiological conditions, such as inflammation, and thus guarantees 100% sensitivity and specificity. The importance of KOC as a tumor indicator also results from the fact that investigator-dependent influences can be ruled out absolutely. As a surrogate parameter, KOC can therefore significantly improve cytological diagnostic reliability. In addition, reference is made to the above explanations regarding the use of KOC as a tumor indicator.
  • TNF-alpha tumor necrosis factor
  • the TNF-alpha gene is packaged with the promoter sequence of the mdr-1 gene in a vector and treated Animals with this vector construct and with chemotherapeutic agents that act on the promoter sequences of the mdr-1 gene turn on the production of TNF alpha, prevent the formation of resistance and promote the destruction of the tumor cell by apoptosis.
  • chemotherapy which is stressful for the patient, must also be carried out.
  • therapy with cisplatin cis-diaminedichloroplatinum
  • cis-diaminedichloroplatinum is used as an active agent in a variety of malignant diseases as a chemotherapeutic agent.
  • the KOC promoter is activated during the malignant transformation of a cell (see below Example 6), this is excellently suitable as a control unit for a so-called "gene-directed enzyme pro drug (suicide gene) therapy" (GDEPT) for the treatment of a large number of malignant diseases.
  • GDEPT gene-directed enzyme pro drug
  • the HSV-TK gene in combination with the application of ganciclovir, which becomes toxic through phosphorylation via the HSV-TK
  • a tumor suppressor gene for example p53, p16, p21, DPC4, APC, etc.
  • an apoptosis-inducing gene for example bad, caspases, etc., functionally linked to the KOC promoter.
  • the present invention also relates to the use of the DNA sequence of the KOC promoter shown in FIG. 9 or the nucleic acid sequence which deviates therefrom, whose biological function essentially corresponds to that of the KOC promoter, for gene therapy cancer treatment.
  • the above explanations apply analogously with regard to the KOC-DNA sequences.
  • the present invention relates to a method for identifying compounds which bind to the DNA sequence of the KOC promoter according to the invention and modulate its activity, the method comprising the following steps: a) bringing a DNA sequence of the KOC promoter according to the invention into contact with a Test compound in a cellular assay; and b) determining the modulation of the activity of the KOC promoter, where modulation indicates that the test compound is active.
  • test compounds can be very different compounds, both naturally occurring and synthetic, organic and inorganic compounds, and also polymers, for example oligopeptides, polypeptides, oligonucleotides and polynucleotides, as well as small molecules, antibodies, sugars, fatty acids, nucleotides and nucleotide and Analogs, analogs of course occurring structures, for example peptide "imitators", nucleic acid analogs etc., and numerous other compounds. Transcription factors are particularly suitable as test compounds.
  • test compound When performing the cellular assay, it must be ensured that the test compound is brought into contact with the DNA sequence of the KOC promoter which controls the transcription of a reporter gene under such conditions that specific binding is made possible. Then it is preferably determined in the same test system whether the transcription of the promoter functionally linked to the reporter gene has been modulated by the presence of the test compound.
  • suitable reporter genes are GFP, Lacz, luciferase or CAT.
  • the values found in terms of the transcription rate are preferably compared with the values in a second test system that differs from the first only in the absence of the test compound.
  • suitable assay formats for the identification of compounds that affect the modulation of the activity of the KOC promoter are well known in the biotechnological and pharmaceutical industries and additional assays and variations of the assay provided above for illustration are obvious to the person skilled in the art.
  • Changes in promoter activity can be measured by any suitable method. Changes in expression level can be examined using methods well known to those skilled in the art. This includes monitoring the mRNA concentration, eg using suitable probes or primers, immunoassays for protein concentration, RNAse protection assays, amplification assays or any other means suitable for detection that is known in the art. Further detection methods regarding the activation of the promoter depend on the specific properties of the respective reporter gene.
  • the search for compounds which are effective for modulating the activity of the KOC promoter can also be carried out on a large scale, for example by screening a very large number of candidate compounds in substance libraries, the substance libraries being synthetic or natural molecules, eg cDNAs from expression libraries.
  • the test compound is part of a substance library.
  • a large number of potentially useful molecules can be screened in a single test. For example, if a field of 1000 compounds is to be screened, in principle all 1000 compounds can be placed in a microtiter plate well and tested simultaneously. If a promoter modulator is discovered, the pool of 1000 can then be divided into 10 pools of 100 and the process repeated until an individual modulator is identified. In any event, the production and simultaneous screening of large banks of synthetic molecules can be carried out using well known combinatorial chemistry techniques, see for example van Breemen, Anal. Chem. 69 (1997), 2159-2164 and Lam, Anticancer Drug Des. j2 (1997), 145-167.
  • the method according to the invention can also be greatly accelerated as high throughput screening.
  • the assays regarding promoter modulation described here can be modified accordingly for use in such a method. It will be apparent to those skilled in the art that numerous methods are available for this purpose.
  • a large number of potentially useful promoter activity-modifying compounds can be screened in extracts from natural products as a starting material. Such extracts can come from a large number of sources, for example the species fungi, actinomycetes, algae, insects, protozoa, plants and bacteria.
  • the extracts that show modulation can then be analyzed to isolate the active molecule. See, for example, Turner, J. Ethnopharmacol. 51 (1-3) (1996), 39-43 and Suh, Anticancer Res. 15 (1995) 233-239.
  • the compounds found which modulate the activity of the KOC promoter can in many cases be used therapeutically, for example in the context of tumor therapy.
  • FIG. 1 DNA sequence of the gene coding for the RNA-binding protein KOC and amino acid sequence derived therefrom
  • Figure 2 Proliferation of cells that express KOC and p210 and cells that only express p210
  • Figure 3 Growth of cells expressing KOC and p210 and cells expressing only p210
  • Figure 4 Resistance of cells that express KOC and p210 and cells that only express p210. towards dexamethasone
  • Fig. 5 Overexpression of the embrvonal marker IGF-II in transgenic mice
  • Fig. 6 Use of KOC as a molecular biological tumor indicator
  • Fig. 9 DNA sequence of the KOC promoter
  • Example 1 Overexpression of KOC leads to apoptosis resistance in adult pre-B lines
  • Murine pre B cells were isolated from either adult bone marrow or fetal liver. The tibiae and femura of mice were isolated to isolate the adult bone marrow. Then they were sprayed with medium (DMEM, Life Technologies, Düsseldorf, Germany). To isolate the fetal progenitor cells, the liver was isolated from day 15 mouse embryos. This was then ground through a sterile cell culture sieve, releasing the individual blood precursor cells. 1 X 10 7 cells per 6 cm were cultivated from adult bone marrow and fetal liver. Both the adult cells and the fetal cells could be cultivated comparatively easily in vitro and thus analyzed for differences in gene expression and for functional differences. Different in vitro culture systems were available for both cell populations.
  • One system was to cultivate the cells on a stromal cell line in the presence of the growth factor Interleukin 7 (R&D Systems, Wiesbaden, Germany).
  • the current cell line ST2 was used in the present case.
  • the cells were expanded until they were approximately 80% confluent. Then they were irradiated with 3000 rad. Cells treated in this way were growth-inactive, but still had a metabolism for a few days.
  • Bone marrow or fetal liver cells were plated on this cell line with a cell density of 2 x 10 6 cells with a concentration of 10ng IL7 per ml. Under these conditions, only pre-B cells grew. The cells were plated onto fresh stromal cells twice a week.
  • the bone marrow or the fetal liver cells with the comparatively low tumorigenic oncogene p210 BCR-ABL transformed.
  • This is a fusion protein that is produced by a chromosomal translocation, with parts of the BCR (break point dark region) gene from chromosome 22 fused to c-ABL (tyrosine kinase) on chromosome 9 (Philadelphia chromosome), resulting in the kinase c-ABL is activated.
  • the translocation mentioned is associated with chronic myeloid leukemia. Retroviral infection was performed.
  • p210 BCR-ABL was cloned into the retroviral vector pBMNZ (available from Garry Nolan, Stanford; vector map: http://www.stanford.edu/group/nolan/pmaps.htmp).
  • 10 7 cells were incubated with 3 ml of retroviral supernatant in the presence of 8 mg / ml polybrene in 50 ml conical tubes for at least 3 hours. The cells were then plated with IL7 on stroma for 48 hours. After 48 hours, IL7 was washed out and the cells were plated without IL7.
  • BCR-ABL made the pre-B cells IL7 independent, only cells that had been infected with the retrovirus coding for BCR-ABL grew out (FIG. 3). A selection for eg G418 could therefore not be made.
  • the BCR-ABL transformed cells were initially IL7-independent and later also stroma-independent. However, the cells transformed in this way were still able to differentiate B cells that mature in vivo.
  • adult pre B cells differ from fetal ones by the expression of two genes: the terminal deoxynucleotide transferase (TdT) and the "myosin light chain 2" (PLRLC) are expressed in adult pre B cells, but not in fetal ones .
  • TdT terminal deoxynucleotide transferase
  • PLRLC myosin light chain 2
  • fetal pre B cells are resistant to steroids, while adult cells become apoptotic after steroid administration.
  • fetal pre B cells can be kept in culture indefinitely in vitro, while the adult cells die after a few months of passage.
  • KOC is expressed in fetal pre B cells but not in adult ones. With KOC there is a marker available to discriminate fetal pre B cells from adults.
  • Example 1 After the clear phenotypic differences between the two cell populations described in Example 1 could be observed, it seemed sensible to create a gene expression profile of these cells using the "Gene Chip” ® system from Affymetrix.
  • This is an oligonucleotide array that is hybridized with different fluorescence-labeled RNA of the respective cell population. The specificity of the hybridization is ensured by the presence of 20 nucleotide probes per gene with perfect sequence agreement and 20 nucleotide probes with a base mismatch.
  • numerous genes could be identified that are differentially expressed. For example, Cyclin DI and IGF-II were only detectable in the cells that also expressed KOC in addition to p210.
  • the coding cDNA of the human KOC gene was cloned in sense orientation directly behind the metallothionein promoter of the expression vector MT-LCR 2999B4 (Palmiter et al., 1993, Mol Cell Biol, 13, 5266-5275 ).
  • the DNA construct (Dral fragment containing the complete open reading frame of KOC was cloned into the Nrul site of the MT-LCR2999B4) was cut with the restriction endonuclease Sall (eg from Röche, Penzberg). The cut construct was injected into the female pronucleus according to the standard protocol using a microinjection system (standard protocol described in: "The Molecular Biology of the Gene", James D.
  • Transgenic Mice Mice with new germ line genes, p. 814 ff.). The cells were then transferred to a pseudopregnant female. The animals which integrated the transgenic construct were identified by means of PCR and Southern blot analysis of the genomic DNA from tail tips of the 1-2 month old mice. These founders were crossed with B6 mice. The lines that inherit the transgene were determined by renewed PCR analysis of the genomic DNA of the offspring of this F1 generation. 02/20036
  • the genomic DNA was isolated from mouse tails using the "Qiagen tissue Kit” and was carried out according to the manufacturer's protocol (Qiagen GmbH, Hilden).
  • Taq polymerase (5U / ⁇ l) O. ⁇ l ddH 2 O ad 50 ⁇ l
  • Transgenic mice were characterized by Western blot analysis of various organs to identify the transgenic mice that express KOC most strongly. Two of these lines were used for breeding.
  • the blots were incubated with the second anti-rabbit antibody coupled to peroxidase (from Amersham ) incubated for 1h at RT.
  • the detection was carried out after washing three times with TBS using the ECL Western blotting detection reagents (from Amersham).
  • Example 4 Differential diagnosis of malignant tumors compared to normal or inflammatory tissue 40
  • Tissue samples were used that were obtained from tissues / tumors of unclear dignity in the liver and lymph nodes using fine needle puncture. Control samples were taken from inflammatory areas of the colon. The biopsies were taken up in lysis buffer (either standard guanidinium buffer or RLT buffer from Qiagen, Hilden, Germany) and mechanically comminuted.
  • lysis buffer either standard guanidinium buffer or RLT buffer from Qiagen, Hilden, Germany
  • RNAeasy Kit from Qiagen, Hilden. This was followed by a DNase digestion.
  • An RT-PCR was carried out directly with the "One-Step RT-PCR Kit” (from Qiagen, Hilden): Primers used:
  • KOC primer 5'-TGCAGTTTCCGAGTCAGTGT-3 '
  • the KOC gene is located on chromosome 7 in the 7p11.5 region.
  • a chromosome 7 specific genomic library (vector Lawrist 4) was screened with a KOC probe.
  • the DNA of positive clones was digested with different restriction enzymes and separated by gel electrophoresis. The gel was blotted using standard procedures.
  • the DNA fixed on the nylon membrane was hybridized with a radioactively labeled 5'-KOC probe. 41
  • a positive 7 kb fragment was then cloned into the vector Bluescript KS (Pharmacia).
  • the clone was deposited on November 1 with the DSMZ (German Collection of Microorganisms and Cell Cultures GmbH, Braunschweig) under the entry number DSM 13810.
  • the clone was also sequenced.
  • the first 1946 bp upstream from the ATG are shown in FIG. 9.
  • the binding sites of transcription factors such as SP1, SRF, TFIID / TBF, AP1, AP2, BPV-E2, c-Myb, c / EBP, E1A-F, GATA-1, HNF-5, IBP- are located on this DNA sequence. 1, NF-IL6, NF-kB, SP1, T-antigen, TCF-1, v-Myb etc.
  • Example 6 The KOC promoter is only expressed in malignant tissues and tumor cell lines.
  • KOC promoter is only expressed in malignant tissues and tumor cell lines (eg colon and pancreas). No KOC transcripts could be detected in human and also murine adult tissues. 42
  • KOC expression is limited to the thymus and intestinal epithelium, with KOC mainly found in the intestinal crypts. KOC expression is completely switched off two days after birth. Due to the differential gene expression of KOC in pancreatic carcinoma, the expression of the protein was studied in human pancreatic development. For this purpose, poly (A) + RNA from human fetal pancreatic tissues from "The Genetics Institute", Boston, USA was used. This was separated by gel electrophoresis and blotted using standard methods. The Northern blot was then hybridized with a radiolabelled human KOC probe. It was shown that KOC is clearly expressed during the 12th week of pregnancy. The highest KOC expression was observed in the 18th week of pregnancy (FIG. 7b).
  • transcript detection was carried out by RT-PCR, which showed that the KOC promoter is activated only in pancreatic carcinoma tissue, but not in the pancreas in chronic pancreatitis or in healthy pancreas.
  • samples were taken from various tissues and in liquid nitrogen immediately after the surgical removal 43
  • RNA extraction from this human pancreatic tissue was carried out with the RNAeasy Midi Kit according to the manufacturer's protocol (Qiagen). After a DNase I digestion, the mRNA was rewritten directly into cDNA.
  • commercially available reverse transcriptases e.g. Superscript II RT, Gibco BRL
  • the primers of the acidic ribosomal phosphoprotein were used for an internal control PCR.
  • This protein is known to be present in normal, inflammatory and malignant pancreatic Tissue is expressed equally strongly (forward primer: 5'CTGGCTAAGTTGGT TGCTTT-3 '; reverse primer: 5'-GCAGCT-GATCAAGACTGGA-3'; attachment temperature 58 ° C; 18 cycles).
  • KOC primers were used for the actual KOC RT-PCR: Forward primer: 5'-TGCAGTTTCCGAGTCAGT-3 '; Reverse primer: 5'- ATATCGGAAACCTCAGCGAG-3 '; Annealing temperature 55 ° C; 35 cycles).
  • the amplified DNA fragments were visualized by gel electrophoretic separation in an ethidium bromide-stained agarose gel under UV light. The results are shown in Figure 8. The following findings were obtained for the individual tissue samples:
  • pancreatic tissue 0/6 positive; Chronic pancreatitis: 0/6 positive; Healthy colon tissue: 0/2 positive; Various tumors: 2/2 positive; Pancreatic carcinoma tissue: 7/7 positive. 44
  • Example 7 Regression of a tumor by administration of an adenovirus with a cDNA encoding TNF-alpha which is under the control of the KOC promoter
  • adenovirus was used as a vector to investigate the possible suitability of the KOC promoter for gene therapy treatment of a tumor.
  • the KOC promoter sequence was functionally cloned by homologous recombination into the adenoviral vector adenovirus type 5 (ATCC, VR-5), so that the E1A gene (which is essential for the replication of the adenovirus) was selectively only in KOC-positive cells is expressed (Ad.KOC-E1)
  • Ad.KOC-E1 adenoviral vector adenovirus type 5
  • the E1A gene which is essential for the replication of the adenovirus
  • the TNF-alpha cDNA was cloned into this construct under the control of the KOC promoter (Ad.KOC-E1 / KOC-TNF); this procedure is described in Kurihara et al. (J. Clin.
  • the virus was produced by infection in the human embryonic kidney cell line (HEK293, ATCC).
  • tumor cells panic carcinoma cells Panel or MiaPaCa2; available from the Amercican Type Culture Collection (ATCC)
  • ATCC Amercican Type Culture Collection
  • the tumors were grown to a size of 1 cm.
  • a clear regression of the tumor was observed after intratumoral injection of the Ad.KOC-E1 / KOC-TNF construct.
  • the antitumor effect of this adenoviral construct was confirmed in the histopathological analysis.
  • HSV-tk is under the control of the KOC promoter (Ad.KOC-tk, adenovirus type 5) is used to form the HSV-tk after infection with this virus in KOC-expressing tumor cells (see above) and with simultaneous administration of ganciclovir, this non-toxic substance was converted into a toxic substance by phosphorylation, as a result of which the tumor cells were destroyed.
  • Example 8 Use of KOC as a diagnostic tool to discriminate benign and malignant lesions from biopsy material
  • RNA lysis buffer 50 g guanidinium thiocyanate, 2.5 ml 1M sodium citrate pH 7.0, 0.5 g N-lauryl sarcosine, 0.7 ml 2-mercaptoethanol in 100 ml H 2 O.
  • the total RNA was isolated from the biopsies using the "RNAeasy Mini Kit” (Qiagen).
  • RT-PCR reaction was carried out using the "One-Step RT PCR Kit” (from Qiagen).
  • the PCR conditions were as follows:
  • KOC primers used reverse: 5'-TGCAGTTTCCGAGTCAGT-3 'forward: ⁇ '-ATATCGGAAACCTCAGCGAG-S' annealing temperature: 55 ° C, 35 cycles
  • the amplified DNA fragments are visualized by gel electrophoretic separation in an ethidium bromide-stained agarose gel under UV light.
  • Example 9 Stimulation of CD8 + T cells against the KOC protein and lysis of carcinoma cells expressing the KOC protein.
  • Peripheral mononuclear cells are obtained from a healthy donor and subjected to a so-called ELISPOT analysis.
  • the principle of this experiment is that lymphocytes in culture vessels are stimulated with specific antigens. If the lymphocytes are activated because they recognize the antigen, the activated lymphocytes release cytokines, which in turn bind to specific antibodies which are immobilized on the bottom surface of the culture vessels. After the lymphocytes have been washed out, the bound cytokines can then be detected in the culture vessels with the aid of a second antibody, which is made visible in a subsequent color reaction.
  • Peripheral blood lymphocytes were purified from an HLA-A0201 positive healthy subject by density centrifugation using a Ficoll Paque ® gradient. T-lymphocytes were obtained by separating the B-lymphocytes or the monocytes using antibody-coupled magneto beads (CD11, CD16, CD19, CD36 and CD56) (Pant T cell isolation kit * , Milteny, Bergisch Gladbach, Germany). About 2 x 10 7 T cells were obtained from 30 ml of blood.
  • HLA-A0201 restricted peptides of the KOC protein were identified using a software system from the NIH (NIH bioinformation Service [httpJbimas.dcrt.nih.gov.cgi- bin / molbio / ken_pa rker_comboform).
  • the peptides were as follows: 47
  • the isolated T cells were incubated with T2 cells which were (a) loaded with a mixture of the above 9mer peptides (10 ⁇ g / peptide) and (b) with a mixture of the above 10mer peptides (10 ⁇ g / peptide).
  • the T cells were restimulated weekly for 6 weeks. In each case 10 7 T cells were cocultivated with 2 ⁇ 10 6 peptide-loaded T2 cells in 24 perforated plates.
  • the reactivity to the peptide-loaded T2 cells was determined weekly, starting on day 0 of the experiment, by performing an IFN- ⁇ Elispot analysis. On day 28, reactivity was observed by the mixture of (a) (400 specific cells per million cells). The main reactivity was directed against the peptide 199 (1000 specific cells / 1,000,000 cells). Less activity was observed against the mixture of (b) (150 specific cells / 1,000,000 cells). Here the peptide 33 showed the highest reactivity (600 specific cells / 1,000,000 cells).
  • the activated CD8 + T cells were incubated with the HLA A0201 + pancreatic carcinoma cell panels, which express the KOC protein.
  • the kidney cells HEK293 were used as controls 48
  • Cytology poorly differentiated epithelial. neoplasia; PaCa metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un médicament contenant une protéine KOC liant l'ADN ou une séquence d'ADN codant cette protéine. L'invention concerne en outre un procédé de diagnostic en matière de tumeurs associées à l'expression de KOC, ainsi que différentes utilisations du médicament selon l'invention, de préférence pour induire artificiellement la pluripotentialité de cellules organiques. L'invention concerne en outre une séquence d'ADN du promoteur de KOC, ledit promoteur de KOC se caractérisant en ce qu'il n'est activé que dans des tissus embryonnaires ou des tumeurs malignes. L'invention concerne par ailleurs différentes utilisations du promoteur de KOC.
EP01957753A 2000-09-06 2001-08-01 Medicament comprenant une sequence d'adn codant la proteine koc liant l'arn, une proteine koc ou une sequence d'adn du promoteur koc Withdrawn EP1317275A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10043964 2000-09-06
DE10043964 2000-09-06
DE10106829A DE10106829A1 (de) 2000-09-06 2001-02-14 Arzneimittel mit einer für das RNA-bindende KOC-Protein kodierenden DNA-Sequenz, einem KOC-Protein oder einer DNA-Sequenz des KOC-Promotors
DE10106829 2001-02-14
PCT/DE2001/002948 WO2002020036A1 (fr) 2000-09-06 2001-08-01 Medicament comprenant une sequence d'adn codant la proteine koc liant l'arn, une proteine koc ou une sequence d'adn du promoteur koc

Publications (1)

Publication Number Publication Date
EP1317275A1 true EP1317275A1 (fr) 2003-06-11

Family

ID=26006945

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01957753A Withdrawn EP1317275A1 (fr) 2000-09-06 2001-08-01 Medicament comprenant une sequence d'adn codant la proteine koc liant l'arn, une proteine koc ou une sequence d'adn du promoteur koc

Country Status (3)

Country Link
EP (1) EP1317275A1 (fr)
AU (1) AU2001279581A1 (fr)
WO (1) WO2002020036A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147143A1 (en) * 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP2172211B1 (fr) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition de peptide associé aux tumeurs et vaccin anti-cancer associé pour le traitement de glioblastome (GBM) et autres cancers
AU2014271235B2 (en) * 2008-10-01 2017-03-02 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
BR112017002206A2 (pt) 2014-08-04 2017-11-21 Oncotherapy Science Inc peptídeo derivado de koc1 e vacina incluindo o mesmo

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255055B1 (en) * 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US6297364B1 (en) * 1998-04-17 2001-10-02 Ludwig Institute For Cancer Research Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0220036A1 *

Also Published As

Publication number Publication date
WO2002020036A1 (fr) 2002-03-14
AU2001279581A1 (en) 2002-03-22

Similar Documents

Publication Publication Date Title
DE69630153T2 (de) Diagnose der Tumorausbreitung
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE69521002T3 (de) Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
DE69625678T2 (de) Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
DE69524182T2 (de) 17Q-Verbundenes Ovarial- und Brustkrebs Empfindlichkeitsgen
DE69633664T2 (de) Genetische marker für brust und eierstockkrebs
DE68928491T2 (de) Erzeugnisse und verfahren zur regelung der suppression von neoplastischen phenotypen
DE69829857T2 (de) Hypoxie-regulierte gene
DE69633272T2 (de) Methoden zur Krebsbehandlung und -kontrolle
DE69635349T2 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
KR101339489B1 (ko) 페리오스틴의 신규한 용도
DE69722035T2 (de) Neue testmethode, um den differenzierungszustand von bauchspeicheldrüsenzellen eines säugetieres festzustellen.
EP1317275A1 (fr) Medicament comprenant une sequence d'adn codant la proteine koc liant l'arn, une proteine koc ou une sequence d'adn du promoteur koc
DE69733861T2 (de) Verwendung von neuronalem apoptose-inhibitorprotein
WO1997023611A2 (fr) Sequences d'acide nucleique de genes des proteines du groupe a grande mobilite et leurs utilisations
JP2002503460A (ja) 創傷治癒のための組成物および方法
DE69631041T2 (de) Promotor des utrophingens
EP3424944A1 (fr) Protéine recombinante pour la prévention ou le traitement de la fibrose tissulaire et composition pour la prévention ou le traitement de la fibrose tissulaire comprenant celle-ci
DE10106829A1 (de) Arzneimittel mit einer für das RNA-bindende KOC-Protein kodierenden DNA-Sequenz, einem KOC-Protein oder einer DNA-Sequenz des KOC-Promotors
US11028139B2 (en) Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same
Duan et al. Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson’s disease
CN101237884A (zh) 与低氧应激反应有关的Int6蛋白及其用途
EP1646649A1 (fr) 7a5/pronostine et utilisation dans le diagnostic tumoral et la therapie tumorale
WO2000050451A2 (fr) Proteine (tp) impliquee dans le developpement du systeme nerveux central
EP1248835A2 (fr) Fibroblaste genetiquement modifie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030407

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20041119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050301